Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- PEDIndependent statistical analysis of Use of Pedometers to Measure and Increase Walking Among Patients With ESRD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pediatric Aggression and Violence: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Aggression and Violence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01253343).
- Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01119248).
- Pediatric Zylet Safety and Efficacy Study: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Zylet Safety and Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00420628).
- Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: Complete Statistical AnalysisIndependent statistical analysis of Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00944073).
- Peer Partners to Improve Physical Activity in Older Latino and Latina Adults With Parkinson’s Disease.: Complete Statistical AnalysisIndependent statistical analysis of Peer Partners to Improve Physical Activity in Older Latino and Latina Adults With Parkinson's Disease.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Peer Support Dyads in Churches: Complete Statistical AnalysisIndependent statistical analysis of Peer Support Dyads in Churches: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03463941).
- Peer to Peer Delivery of Behavioral Activation: Complete Statistical AnalysisIndependent statistical analysis of Peer to Peer Delivery of Behavioral Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02292849).
- PeerPrEPIndependent statistical analysis of Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PEGASUS CRTIndependent statistical analysis of PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00146848).
- PEGHOPEIndependent statistical analysis of An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy: primary…
- Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434330).
- Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): Complete Statistical AnalysisIndependent statistical analysis of Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PEGRescueIndependent statistical analysis of Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG "Rescue": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV): Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV): primary endpoint results, effect estimate with confidence interval,…
- Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer: primary endpoint results, effect estimate…
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02658019).
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02940496).
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Pembrolizumab +/- Bevacizumab for Recurrent GBM: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab +/- Bevacizumab for Recurrent GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337491).
- Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: primary…
- Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02688608).
- Pembrolizumab in Combination With CRT for LA-SCCHN: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With CRT for LA-SCCHN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02586207).
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03332498).
- Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02964559).
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02267603).
- Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337686).
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…
- Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…